University of California, Irvine

About: University of California, Irvine is a education organization based out in Irvine, California, United States. It is known for research contribution in the topics: Population & Galaxy. The organization has 47031 authors who have published 113602 publications receiving 5521832 citations. The organization is also known as: UC Irvine & UCI.

Zinc oxide nanostructures: synthesis and properties.

Abstract: This article provides a comprehensive review of the current research activities that focus on the ZnO nanostructure materials and their physical property characterizations. It begins with the synthetic methods that have been exploited to grow ZnO nanostructures. A range of remarkable characteristics are then presented, organized into sections describing the mechanical, electrical, optical, magnetic, and chemical sensing properties. These studies constitute the basis for developing versatile applications of ZnO nanostructures.

Detecting activities of daily living in first-person camera views

Abstract: We present a novel dataset and novel algorithms for the problem of detecting activities of daily living (ADL) in firstperson camera views. We have collected a dataset of 1 million frames of dozens of people performing unscripted, everyday activities. The dataset is annotated with activities, object tracks, hand positions, and interaction events. ADLs differ from typical actions in that they can involve long-scale temporal structure (making tea can take a few minutes) and complex object interactions (a fridge looks different when its door is open). We develop novel representations including (1) temporal pyramids, which generalize the well-known spatial pyramid to approximate temporal correspondence when scoring a model and (2) composite object models that exploit the fact that objects look different when being interacted with. We perform an extensive empirical evaluation and demonstrate that our novel representations produce a two-fold improvement over traditional approaches. Our analysis suggests that real-world ADL recognition is “all about the objects,” and in particular, “all about the objects being interacted with.”

Syskill & webert: Identifying interesting web sites

Abstract: We describe Syskill & Webert, a software agent that learns to rate pages on the World Wide Web (WWW), deciding what pages might interest a user. The user rates explored pages on a three point scale, and Syskill & Webert learns a user profile by analyzing the information on each page. The user profile can be used in two ways. First, it can be used to suggest which links a user would be interested in exploring. Second, it can be used to construct a LYCOS query to find pages that would interest a user. We compare six different algorithms from machine learning and information retrieval on this task. We find that the naive Bayesian classifier offers several advantages over other learning algorithms on this task. Furthermore, we find that an initial portion of a web page is sufficient for making predictions on its interestingness substantially reducing the amount of network transmission required to make predictions.

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

Abstract: (Headache 2010;50:921-936) Objective.— To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Background.— Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Few preventive treatments have been investigated and none is specifically indicated for chronic migraine. Methods.— The 2 multicenter, pivotal trials in the PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy clinical program each included a 24-week randomized, double-blind phase followed by a 32-week open-label phase (ClinicalTrials.gov identifiers NCT00156910, NCT00168428). Qualified patients were randomized (1:1) to onabotulinumtoxinA (155-195 U) or placebo injections every 12 weeks. Study visits occurred every 4 weeks. These studies were identical in design (eg, inclusion/exclusion criteria, randomization, visits, double-blind phase, open-label phase, safety assessments, treatment), with the only exception being the designation of the primary and secondary endpoints. Therefore, the predefined pooling of the results was justified and performed to provide a complete overview of between-group differences in efficacy, safety, and tolerability that may not have been evident in individual studies. The primary endpoint for the pooled analysis was mean change from baseline in frequency of headache days at 24 weeks. Secondary endpoints were mean change from baseline to week 24 in frequency of migraine/probable migraine days, frequency of moderate/severe headache days, total cumulative hours of headache on headache days, frequency of headache episodes, frequency of migraine/probable migraine episodes, frequency of acute headache pain medication intakes, and the proportion of patients with severe (≥60) Headache Impact Test-6 score at week 24. Results of the pooled analyses of the 2 PREEMPT double-blind phases are presented. Results.— A total of 1384 adults were randomized to onabotulinumtoxinA (n = 688) or placebo (n = 696). Pooled analyses demonstrated a large mean decrease from baseline in frequency of headache days, with statistically significant between-group differences favoring onabotulinumtoxinA over placebo at week 24 (−8.4 vs −6.6; P < .001) and at all other time points. Significant differences favoring onabotulinumtoxinA were also observed for all secondary efficacy variables at all time points, with the exception of frequency of acute headache pain medication intakes. Adverse events occurred in 62.4% of onabotulinumtoxinA patients and 51.7% of placebo patients. Most patients reported adverse events that were mild to moderate in severity and few discontinued (onabotulinumtoxinA, 3.8%; placebo, 1.2%) due to adverse events. No unexpected treatment-related adverse events were identified. Conclusions.— The pooled PREEMPT results demonstrate that onabotulinumtoxinA is an effective prophylactic treatment for chronic migraine. OnabotulinumtoxinA resulted in significant improvements compared with placebo in multiple headache symptom measures, and significantly reduced headache-related disability and improved functioning, vitality, and overall health-related quality of life. Repeat treatments with onabotulinumtoxinA were safe and well tolerated.